Brought to you by 
Miraculins licenses biomarkers from Mount Sinai Hospital
03 Apr 2013
Executive Summary
Miraculins (noninvasive tests for unmet medical needs) has licensed exclusive rights to a portfolio of biomarkers from Mount Sinai Hospital of Toronto that will be used to develop assays for the early detection of preeclampsia.
Deal Industry
- Biotechnology
- In Vitro Diagnostics
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Miraculins licenses biomarkers from Mount Sinai Hospital
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice